Skip to main content
SpringerLink
Log in

Kleine Unterschiede bei der HIV-Prä-Expositionsprophylaxe

PrEP: Profitieren Frauen weniger?

HIV pre-exposure prophylaxis in women

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

In den Hochprävalenzländern Afrikas benötigen Frauen dringend eine selbstbestimmte Form der HIV-Prävention. Die PrEP scheint bei ihnen jedoch eine geringere Schutzwirkung zu haben als bei Männern.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D; FEM-PrEP Study Group. Preexposureprophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411–22.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S,Mkhize B, Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372: 509–18.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3: 112re4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hillier SL, Meyn LA, Bunge K, et al.Impact of vaginal microbiota on genital tissue and plasma concentrations of tenofovir. Presented at: CROI 2017. Seattle, WA; February 13-16, 2017. Abstract 86LB.

  5. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Pather A, Naidoo L, Husnik M, Richardson BA, Parikh UM, Mellors JW, Marzinke MA, Hendrix CW, van der Straten A, Ramjee G, Chirenje ZM, Nakabiito C, Taha TE, Jones J, Mayo A, Scheckter R, Berthiaume J, Livant E, Jacobson C, Ndase P, White R, Patterson K, Germuga D, Galaska B, Bunge K, Singh D, Szydlo DW, Montgomery ET, Mensch BS, Torjesen K, Grossman CI, Chakhtoura N, Nel A, Rosenberg Z, McGowan I, Hillier S; MTN-020-ASPIRE Study Team. Use of a Vaginal Ring ContainingDapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016 Feb 22. [Epub ahead of print]

  6. Annalene Nel, M.B., Ch.B., Ph.D., Neliëtte van Niekerk, M.Com., Saidi Kapiga, M.D., Sc.D., M.P.H., Linda-Gail Bekker, M.B., Ch.B., Ph.D., Cynthia Gama, M.B., Ch.B., Katherine Gill, M.B., Ch.B., Anatoli Kamali, M.B., Ch.B., Ph.D., Philip Kotze, M.B., Ch.B., M.Med., Cheryl Louw, M.B., Ch.B., Zonke Mabude, M.A., Nokuthula Miti, M.B., Ch.B., Sylvia Kusemererwa, M.B., Ch.B., M.P.H., Hugo Tempelman, M.D., Hannelie Carstens, Ph.D., Brid Devlin, Ph.D., Michelle Isaacs, B.Pharm., B.Sc., Mariëtte Malherbe, B.Sc., Winel Mans, M.B., Ch.B., Jeremy Nuttall, M.Sc., Marisa Russell, B.Sc., Smangaliso Ntshele, Dip.G.N.M., Marlie Smit, B.Diet., Leonard Solai, M.B.A., Patrick Spence, Ph.D., John Steytler, M.B., Ch.B., Kathleen Windle, B.Sc., Maarten Borremans, M.Sc., Sophie Resseler, M.Sc., Jens Van Roey, M.D., Wim Parys, M.D., Tony Vangeneugden, Ph.D., Ben Van Baelen, M.Sc., and Zeda Rosenberg, Sc.D., for the Ring Study Team Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women N Engl J Med 2016; 375:2133-2143December 1, 2016DOI: 10.1056/NEJMoa1602046

  7. Riddler S, Balkus J, Mellors J, Parikh U, Akello C, Dadabhai S, Mhlanga F, O’Rourke C, Baeten J NNRTI-containing ART is effective for dapivirine ring breakthrough HIV-1 infection. Presented at CROI 2017. Seattle, WA; February 13-16, 2017. Abstract 952.

  8. Gulick R, Wilkin T, Chen Y, et al. HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in United States (U.S.) women. Presented at: 21st International AIDS Conference (AIDS 2016). July 18-22, 2016. Durban, South Africa. Abstract TUAC0102.

Download references

Author information

Authors and Affiliations

  1. Med. Klinik II, Universitätsklinikum Frankfurt a. M., Theodor-Stern-Kai 7, D-60590, Frankfurt, Deutschland

    Annette Haberl (Leiterin des Bereichs HIV und Frauen am HIVCENTER)

Authors
  1. Annette Haberl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annette Haberl.

Additional information

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haberl, A. PrEP: Profitieren Frauen weniger?. MMW - Fortschritte der Medizin 159 (Suppl 2), 42–44 (2017). https://doi.org/10.1007/s15006-017-9736-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9736-9

Keywords

Search

Navigation